Slide 1: ViroGates A/S Investor Presentation
ViroGates ViroGates A/S Investor Presentation 26 May 2020 Aktieinfo, Copenhagen
Slide 2: Forward-looking statements
ViroGates Forward-looking statements Certain information set forth and given in this presentation contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking st
Slide 3: ViroGates produces and sells three prognostic biomarker products for the healthcare sector in Europe
ViroGates 3 ViroGates produces and sells three prognostic biomarker products for the healthcare sector in Europe ViroGates suPARnostic® products suPAR is the biomarker detected by ViroGates’ three CE-IVD marked suPARnostic® products and is a protein found in plasma. Description ViroGates has establi
Slide 4: suPARnostic measures suPAR and can help hospitals improve patient care, reduce healthcare costs
ViroGates 4 suPARnostic® measures suPAR and can help hospitals improve patient care, reduce healthcare costs and empower clinical staff Improve patient care Reduce healthcare costs Empower clinical staff
Slide 5: suPAR is a marker of immune activation and a strong predictor of all-cause mortality
ViroGates 5 suPAR is a marker of immune activation and a strong predictor of all-cause mortality across diseases, patients, and age groups suPAR (soluble urokinase Plasminogen Activator Receptor) uPAR DI DII suPAR DI DII suPAR is a stable, unspecific biomarker across diseases A prognostic inflammato
Slide 6: suPARnostic improves patient care and reduces healthcare costs by lowering admissions and hospital length-of-stay
ViroGates 6 suPARnostic® improves patient care and reduces healthcare costs by lowering admissions and hospital length-of-stay Indicative effects of using suPAR Improve patient care 34% more patients classified into low-risk, discharge category and with lower mortality1 Reduce healthcare costs 6% re
Slide 7: suPARnostic empowers clinical staff with more information to make more confident clinical decisions
ViroGates 7 suPARnostic® empowers clinical staff with more information to make more confident clinical decisions Indicative effects of using suPAR Improve patient care “The addition of suPAR to “We believe that suPAR levels National Early Warning Score may provide benefit for triage significantly im
Slide 8: suPARnostic has been used in clinical routine since 2013 and its strengths are well-documented
ViroGates 8 suPARnostic® has been used in clinical routine since 2013 and its strengths are well-documented in scientific studies 8 hospitals with suPAR in 50 hospitals evaluating clinical clinical routine in 4 countries implementation of suPARnostic® in clinical routine across Europe Næstved Hosp.
Slide 9: The suPARnostic TurbiLatex product fits into routine blood work and has been validated
ViroGates 9 The suPARnostic® TurbiLatex product fits into routine blood work and has been validated on analyzers used in clinical biochemistry Easy to use Fits directly into existing work flow and turnaround time in clinical biochemistry with no additional samples or work flow steps needed Validated
Slide 10: More than 17,000 patient samples show suPARnostic's ability to support better triage decisions
ViroGates 10 More than 17,000 patient samples show suPARnostic’s® ability to support physicians in making better triage decisions Supports a decision of… Personal 56% of patients walk in • suPAR <3 ng/ml Discharge • Little risk of life-threatening disease • 30-day mortality rate at <1% 32% of patien
Slide 11: Compared to standard triaging, suPARnostic reveals more low-risk and more high-risk patients
ViroGates 11 Compared to standard triaging, suPARnostic® reveals more low-risk patients and more high-risk patients Triage group Standard triaging (EWS*) suPAR-supported triaging Difference Outcome Share of patients Share of patients %-points Improved patient care and reduced healthcare costs: Low r
Slide 12: ViroGates has a global ~€1 billion market opportunity in Acute Care
ViroGates 12 ViroGates has a global ~€1 billion market opportunity in Acute Care – healthcare savings potential varies across markets Global ViroGates market opportunity in Acute Care Healthcare savings potential in Acute Care (example markets)* Million EUR Million EUR Net healthcare savings Cost of
Slide 13: ViroGates has significant future opportunities beyond Acute Care
ViroGates 13 ViroGates has significant future opportunities beyond Acute Care General Practitioners Private Health Tests ~19 billion EUR market opportunity ~27 billion EUR market opportunity • Health screens and regular visits at • Private Health tests are conducted at the GP offices independent lab
Slide 14: The current focus is on commercialization – most of the IPO proceeds boost commercial execution
ViroGates The current focus is on commercialization – most of the proceeds from the IPO is dedicated to boosting commercial execution Status and outlook Use of proceeds Clinical IP Prepare documentation 0.4 • Ensure adequate product offering 1 • Validate the product clinically 1.0 • Perform health e
Slide 15: ViroGates has an experienced management team and board
ViroGates 15 ViroGates has an experienced management team and board Management Team Non-Executive Board Jakob Knudsen, CEO, LL.M & MBA Dr. Lars Kongsbak (Chairman) • +15 years operational experience in life science • +25 years operational experience in • CEO ViroGates A/S since 2011, CCO and CFO Ega
Slide 16: A Danish region serving seven hospitals became a clinical customer
ViroGates 16 A Danish region serving seven hospitals became a clinical customer - TurbiLatex is now validated on ADVIA® XPT Business highlights in Q1, 2020 • Announced clinical implementation of suPARnostic® Quick Triage at hospitals in Region Zealand and to be conducted by the clinical immunology d
Slide 17: Income Statement (1 January – 31 March 2020)
ViroGates 17 Income Statement (1 January – 31 March 2020) PROFIT & LOSS Q1, Q1, % Amounts in DKK (‘000) Note 2020 2019 change 2019 Net revenue 445 1,105 -60% 3,581 Cost of goods/services sold -147 -90 64% -384 Gross profit 298 1,015 -71% 3,198 Sales and distribution costs 1 -4,402 -2,804 57% -13,921
Slide 18: Balance Sheet (31 March 2020)
ViroGates 18 Balance Sheet (31 March 2020) ASSETS Q1, Q1, % EQUITY AND LIABILITIES Q1, Q1, % Amounts in DKK (‘000) Note 2020 2019 change 2019 Amounts in DKK (‘000) Note 2020 2019 change 2019 Other plant, machinery, tools & equipment 494 86 473% 548 Share capital 3,034 3,034 0% 3,034 Tangible fixed a
Slide 19: Thank you for your attention!
ViroGates 19 Thank you for your attention! Jakob Knudsen +45 2226 1355 jk@virogates.com